Citation:
In Advances in Applied Biotechnology Series, Volume 2, Discoveries in Antisense Nucleic Acids. C. Brakel, Ed. 1989 Portfolio Publishing Company, The Woodlands. 71-
Abstract:
We have devised a class of uncharged sequence-specific nucleic asid-binding oligomers, Neu-Genes(TM) (short for neutral genes), Designed for therapeutic and diagnostic applications. These Neu-Genes(TM) utilize ribonucleosides as starting materials, which are on the order of 30-fold less expensive that the deoxyribonucleosides required for most competing antisense agents. In addition, the easy preparation and purification of Neu-Genes(TM) can be carried out under relatively non-stringent conditions on a large scale. Accordingly, we believe these ribonucleoside-derived Neu-Genes(TM) offer the substantial cost reductions required for practical clinical application of agents targeted against genetic sequences unique to selected pathogens and other pathogenic states.